Holen Sie sich die Stockscreener-App
337.60
1.19%
-4.06
Handel nachbörslich:
336.60
-1.00
-0.30%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$341.66
Offen:
$344.38
24-Stunden-Volumen:
8.22M
Relative Volume:
2.94
Marktkapitalisierung:
$182.21B
Einnahmen:
$37.30B
Nettoeinkommen (Verlust:
$7.80B
KGV:
23.48
EPS:
14.3793
Netto-Cashflow:
$8.60B
1W Leistung:
-4.65%
1M Leistung:
+4.07%
6M Leistung:
+4.06%
1J Leistung:
+16.56%
1-Tages-Spanne:
$334.05
$345.00
1-Wochen-Bereich:
$334.05
$358.30
52-Wochen-Spanne:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
337.60 | 182.21B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,098.57 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.39 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
216.49 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
113.87 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
147.08 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Hold |
| 2026-03-10 | Eingeleitet | Jefferies | Hold |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-20 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Why Amgen’s Repatha is quietly reshaping cholesterol therapy - AD HOC NEWS
Amgen Growth Drivers Surge 24 Percent as New Core Takes Over - HarianBasis.co
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo! Finance Canada
Amgen StockGoldman Sachs trims target after obesity pipeline update - AD HOC NEWS
Amgen Rhode Island - Providence Business News
Amgen Gives Greater Los Angeles Community an Experience to Remember at FIFA Fan Festival - Amgen
What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? - Yahoo Finance
What If Amgen Stock’s Patent Worries Are Hiding Its Real Growth Engine? - Trefis
Medtronic Ruling Supports IRS In Amgen Case, Tax Court Told - Law360
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Amgen's Diversified Business, Emerging Pipeline Drives Positive View, RBC Says - Moomoo
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $370 - Moomoo
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know - sharewise.com
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Amgen Stock’s Gross Margin Story in Q1 2026: What the Numbers Say About a $468 Target - TIKR.com
Amgen Ends Lobbying Relationship With DC Firm - Legis1
How Patent Setback and Drug Wins Will Impact Amgen (AMGN) Investors - simplywall.st
Competitive tension builds around Amgen's Tepezza after a fresh patent ruling - AD HOC NEWS
Amgen Hires Lobbying Counsel on Drug Pricing - Legis1
New phase 3 data put Amgen’s Repatha back in the lipid spotlight - AD HOC NEWS
Amgen Inc. Stock (US0311621009): Jury patent verdict and valuation debate put shares in focus - AD HOC NEWS
Amgen Owes $20 Million in Antibody-Production Tech Patent Trial - Bloomberg Law News
Harbour BioMed Wins $20 Million Patent Verdict Against Amgen - Contract Pharma
AMGN DCF Analysis: Intrinsic Value $292 vs Price $355 - GuruFocus
The litigation lasted five years, and Amgen was found to have willfully infringed. Harbour BioMed stated, 'The favorable ruling is expected to enhance our BD negotiation leverage.' | Quick Read Announcement - 富途牛牛
Amgen Inc. (AMGN) Stock Report: Valuation Insights Amid Robust Dividend Yield and Revenue Growth - DirectorsTalk Interviews
Internal documents reveal: Denmark sues Amgen for millions following MFN exit - medwatch.com
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape - PR Newswire
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Amgen’s Repatha Data Highlights at ADA 2026 Amid Analyst Price Target AdjustmentEarnings Call Highlights - newsline.com
Amgen Repatha Data Highlights Potential in Longevity Sector Following ADA PresentationRevenue Miss Report - newsline.com
Amgen's Repatha Data Bolsters Longevity Profile Amid Analyst Price Target AdjustmentLow Estimate Range - newsline.com
Amgen Shows Repatha Risk Reduction in High-Risk Diabetes Patients; Goldman Sachs Adjusts Price TargetProfit Warning Alert - newsline.com
Healthcare of Ontario Pension Plan Trust Fund Sells 64,867 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Cuts Cardiovascular Risk in High Risk Diabetes Patients - HarianBasis.co
Atlas Capital Advisors Inc. Takes $2.20 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Valuation Looks Split Between Analyst Targets And DCF Upside - simplywall.st
Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna - Insider Monkey
Wall Street Zen Upgrades Amgen (NASDAQ:AMGN) to Buy - MarketBeat
Amgen Inc. Stock (US0311621009): Biotech heavyweight in focus as investors weigh valuation and pipel - AD HOC NEWS
Victory Capital Management Inc. Grows Holdings in Amgen Inc. $AMGN - MarketBeat
State Street Corp Has $10.01 Billion Stock Position in Amgen Inc. $AMGN - MarketBeat
Van ECK Associates Corp Lowers Position in Amgen Inc. $AMGN - MarketBeat
Is Amgen Still Reasonable After Its Strong Run? - Kalkine Media
Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now - Insider Monkey
Korea Investment CORP Trims Stake in Amgen Inc. $AMGN - MarketBeat
Operating expenses (excl. COGS) of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Rhenman & Partners Asset Management AB Acquires Shares of 36,000 Amgen Inc. $AMGN - MarketBeat
First National Bank of Omaha Boosts Position in Amgen Inc. $AMGN - MarketBeat
Amgen taps research firm to reassess Tavneos data - Reuters
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):